Nexstim Oyj
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique whereby pulses of electromagnetic fields target and interact with specific brain regions from outside the head. It provi… Read more
Nexstim Oyj (NXTMH) - Net Assets
Latest net assets as of June 2025: €3.18 Million EUR
Based on the latest financial reports, Nexstim Oyj (NXTMH) has net assets worth €3.18 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.35 Million) and total liabilities (€9.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.18 Million |
| % of Total Assets | 25.75% |
| Annual Growth Rate | 23.13% |
| 5-Year Change | N/A |
| 10-Year Change | 4.37% |
| Growth Volatility | 291.14 |
Nexstim Oyj - Net Assets Trend (2012–2024)
This chart illustrates how Nexstim Oyj's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nexstim Oyj (2012–2024)
The table below shows the annual net assets of Nexstim Oyj from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.70 Million | +30.44% |
| 2023-12-31 | €2.84 Million | -30.29% |
| 2022-12-31 | €4.07 Million | +27.04% |
| 2021-12-31 | €3.20 Million | +318.00% |
| 2020-12-31 | €-1.47 Million | -98.51% |
| 2019-12-31 | €-740.06K | -151.49% |
| 2018-12-31 | €-294.27K | -105.33% |
| 2017-12-31 | €5.52 Million | +23.27% |
| 2016-12-31 | €4.48 Million | +26.33% |
| 2015-12-31 | €3.55 Million | -58.73% |
| 2014-12-31 | €8.59 Million | +460.60% |
| 2013-12-31 | €-2.38 Million | -881.51% |
| 2012-12-31 | €304.81K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nexstim Oyj's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2490783849.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €80.00K | 2.16% |
| Other Comprehensive Income | €56.86 Million | 1536.73% |
| Total Equity | €3.70 Million | 100.00% |
Nexstim Oyj Competitors by Market Cap
The table below lists competitors of Nexstim Oyj ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sino Tactful Co Ltd
TWO:5481
|
$35.66 Million |
|
Apex Frozen Foods Limited
NSE:APEX
|
$35.67 Million |
|
R. Stahl AG NA O.N.
F:RSL2
|
$35.68 Million |
|
Davolink Inc.
KQ:340360
|
$35.69 Million |
|
Renaissance Global Limited
NSE:RGL
|
$35.64 Million |
|
MEB Corp. PCL
BK:MEB
|
$35.64 Million |
|
Tetratherix Ltd
AU:TTX
|
$35.63 Million |
|
Kafein Yazilim
IS:KFEIN
|
$35.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nexstim Oyj's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,836,337 to 3,699,857, a change of 863,520 (30.4%).
- Net loss of 892,288 reduced equity.
- Share repurchases of 1,814,570 reduced equity.
- New share issuances of 1,814,571 increased equity.
- Other comprehensive income increased equity by 1,814,572.
- Other factors decreased equity by 58,765.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-892.29K | -24.12% |
| Share Repurchases | €1.81 Million | -49.04% |
| Share Issuances | €1.81 Million | +49.04% |
| Other Comprehensive Income | €1.81 Million | +49.04% |
| Other Changes | €-58.77K | -1.59% |
| Total Change | €- | 30.44% |
Book Value vs Market Value Analysis
This analysis compares Nexstim Oyj's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.41x to 16.27x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | €6.30 | €8.90 | x |
| 2013-12-31 | €-75.31 | €8.90 | x |
| 2014-12-31 | €167.70 | €8.90 | x |
| 2015-12-31 | €42.06 | €8.90 | x |
| 2016-12-31 | €35.31 | €8.90 | x |
| 2017-12-31 | €6.55 | €8.90 | x |
| 2018-12-31 | €-0.29 | €8.90 | x |
| 2019-12-31 | €-0.51 | €8.90 | x |
| 2020-12-31 | €-0.40 | €8.90 | x |
| 2021-12-31 | €0.49 | €8.90 | x |
| 2022-12-31 | €0.56 | €8.90 | x |
| 2023-12-31 | €0.42 | €8.90 | x |
| 2024-12-31 | €0.55 | €8.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nexstim Oyj utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.21%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 3.84x
- Recent ROE (-24.12%) is above the historical average (-125.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -885.46% | -84.60% | 0.81x | 13.00x | €-2.73 Million |
| 2013 | 0.00% | -241.31% | 0.61x | 0.00x | €-4.28 Million |
| 2014 | -121.60% | -472.55% | 0.16x | 1.63x | €-11.30 Million |
| 2015 | -277.20% | -388.75% | 0.27x | 2.60x | €-10.18 Million |
| 2016 | -150.33% | -271.20% | 0.24x | 2.33x | €-7.18 Million |
| 2017 | -132.73% | -277.01% | 0.24x | 2.00x | €-7.88 Million |
| 2018 | 0.00% | -230.31% | 0.28x | 0.00x | €-6.12 Million |
| 2019 | 0.00% | -202.58% | 0.44x | 0.00x | €-6.71 Million |
| 2020 | 0.00% | -100.19% | 0.66x | 0.00x | €-3.97 Million |
| 2021 | -25.98% | -13.01% | 0.64x | 3.13x | €-1.15 Million |
| 2022 | 32.12% | 13.72% | 0.93x | 2.51x | €899.94K |
| 2023 | -46.80% | -18.32% | 0.73x | 3.48x | €-1.61 Million |
| 2024 | -24.12% | -10.21% | 0.62x | 3.84x | €-1.26 Million |
Industry Comparison
This section compares Nexstim Oyj's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $50,423,185
- Average return on equity (ROE) among peers: 3.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nexstim Oyj (NXTMH) | €3.18 Million | -885.46% | 2.88x | $35.65 Million |
| Biohit Oyj B (BIOBV) | $13.41 Million | -6.25% | 1.04x | $19.87 Million |
| BBS-Bioactive Bone Substitutes Oyj (BONEH) | $4.42 Million | 8.60% | 1.53x | $854.55K |
| Modulight Oyj (MODU) | $76.15 Million | -6.65% | 0.15x | $17.65 Million |
| Revenio Group Corporation (REG1V) | $107.71 Million | 17.17% | 0.31x | $481.80 Million |